Bath Community Hospital, announced today that Monoclonal Antibodies (mABs) for treatment of COVID-19 will begin on November 8, 2021.
Monoclonal antibodies can effectively decrease hospitalization rates and progression to severe disease for patients with mild to moderate COVID-19.
Having access to monoclonal antibody treatment can be effective if taken early and administered within ten days of symptom onset or as soon as possible after a positive viral test. The FDA has authorized this antibody treatment for emergency use for eligible patients.
What are monoclonal antibody COVID-19 treatments?
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. These antibodies are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.
“Vaccines and a healthy immune system provide the best protection from COVID-19,” said Bath Community Physicians Group Medical Director, Dr. Scott Crosby. “Offering access to this potentially lifesaving treatment, if taken early, can reduce the risk of severe disease, hospitalization, and death.”
Contact your health care provider for a referral, or call 540-679-0768 for more information and scheduling.
Medicare and several commercial insurance companies are covering all costs for patients. To
learn more about treatment costs, contact your insurance provider.
- Bath Community Hospital Using New COVID-19 Testing Platform
- Bath Community Hospital Announces New General Surgeon | Dr. John Sedovy
- Bath Community Hospital 2021 Community Health Needs Assessment
- Bath Community Hospital Helps to Make COVID-19 Testing More Available
- Bath Community Hospital Offering Monoclonal Antibody COVID-19 Treatments